[Study on the clinical characteristics of biphenotypic acute leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2000 Jul;21(7):352-4.
[Article in Chinese]

Abstract

Objective: To analyze the biological characteristics and the treatment outcome of adult biphenotypic acute leukemia.

Methods: Immunophenotypes were examined using indirect immunofluorescence method. Biphenotypic acute leukemia (BAL) was diagnosed according to EGIL scoring system.

Results: (1) The incidence of BAL in acute leukemia was 3.4%. Percentage for coexpression of B lymphoid and myeloid antigens was 68.4%, for T lymphoid and myeloid antigens 21.1%, for B, T lymphoid and myeloid antigens 10.5%. (2) CD(34) was expressed in 43.75% of the BAL cases. (3) Cytogenetic analysis revealed normal and abnormal karyotypes in 41.7% and 58.3% of the BAL cases, respectively. (4) Six of 19 patients achieved completed remission (CR), but the disease free survivals were all less than 6 months. Treatment outcomes were negatively related to the expression of CD(34) antigen and cytogenetic findings. The BAL patients were poorly responded to therapeutic regimens directed to AML.

Conclusion: Coexpression of B/M antigens is the commonest subtype in BAL. BAL had a poor prognosis, especially treated with induction regimen directed to AML.

Publication types

  • English Abstract

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antigens, CD34 / analysis
  • Chromosome Aberrations
  • Female
  • Humans
  • Immunophenotyping
  • Karyotyping
  • Leukemia / drug therapy*
  • Leukemia / genetics
  • Leukemia / pathology*
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Monocytic, Acute / genetics
  • Leukemia, Monocytic, Acute / pathology
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology
  • Male
  • Middle Aged
  • Phenotype
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Treatment Outcome

Substances

  • Antigens, CD34